Last 22 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5.67 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 21.56 | 3.33 | 4.56 | 2.25 | 1.37 | 1.85 | 1.47 | 2.21 | 3.06 | 4.60 | 3.92 | — | 1.52 |
| — | +79.5% | +209.5% | +1.5% | -55.3% | -59.7% | -62.4% | — | +101.1% | +206.4% | +232.5% | — | -67.6% | |
| P/B Ratio | 1.63 | 1.20 | 3.76 | 1.38 | 0.59 | 0.50 | 0.50 | 0.69 | 0.70 | 1.48 | 0.86 | 1.73 | 1.01 |
| — | +141.8% | +651.9% | +99.9% | -16.0% | -66.4% | -41.8% | -60.2% | -30.4% | +62.0% | -17.9% | +65.7% | -27.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Alterity Therapeutics Limited's operating margin was -184.9% in Q4 2025, up 281.2 pp QoQ and up 323.0 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -375.2% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.7% | 98.3% | 96.0% | 96.5% | 96.1% | 96.6% | 97.9% | 99.2% | 98.7% | 98.4% | 98.1% | 113.5% | 94.5% |
| — | +1.8% | -1.9% | -2.7% | -2.6% | -1.8% | -0.2% | -12.6% | +4.4% | +8.7% | +1.6% | +22.4% | +1.7% | |
| Operating Margin | -268.0% | -184.9% | -466.2% | -612.8% | -236.8% | -507.9% | -450.6% | -378.5% | -430.7% | -402.0% | -511.9% | 439.0% | -309.5% |
| — | +63.6% | -3.5% | -61.9% | +45.0% | -26.3% | +12.0% | -186.2% | -39.2% | -43.3% | -121.6% | +239.4% | -52.1% | |
| Net Margin | -223.4% | -129.8% | -446.7% | -595.5% | -342.4% | -377.3% | -336.7% | -226.6% | -279.1% | -274.7% | -454.6% | 421.3% | -304.0% |
| — | +65.6% | -32.7% | -162.8% | -22.7% | -37.3% | +25.9% | -153.8% | +8.2% | +0.9% | -106.6% | +249.4% | -24.2% |
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -43.2% | -19.8% | -66.5% | -80.3% | -32.2% | -22.7% | -25.3% | -16.4% | -18.4% | -20.8% | -38.1% | -71.9% | -40.6% |
| — | +12.6% | -163.0% | -391.0% | -75.0% | -9.0% | +33.7% | +77.3% | +54.8% | +59.1% | +3.6% | -179.9% | -146.1% | |
| ROA | -37.2% | -17.6% | -48.2% | -60.9% | -26.3% | -19.0% | -21.5% | -14.5% | -16.8% | -19.0% | -33.8% | -56.3% | -32.8% |
| — | +7.6% | -124.2% | -319.7% | -56.7% | -0.1% | +36.4% | +74.2% | +48.9% | +53.7% | -3.9% | -146.0% | -114.0% | |
| ROIC | -204.0% | -83.4% | -240.3% | -283.2% | -52.7% | -116.1% | -451.2% | -317.2% | -231.3% | -854.0% | -2069.3% | -3025.3% | -733.8% |
| — | +28.2% | +46.7% | +10.7% | +77.2% | +86.4% | +78.2% | +89.5% | +68.5% | -277.2% | -733.1% | -308.1% | -226.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 110.2% YoY to 12.98x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
| — | -60.2% | +1201.9% | +248.0% | +1323.3% | +327.9% | — | +3.5% | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 12.98 | 12.98 | 3.84 | 3.54 | 4.90 | 6.17 | 6.35 | 7.07 | 11.92 | 10.92 | 12.28 | 4.88 | 4.43 |
| — | +110.2% | -39.5% | -49.9% | -58.9% | -43.5% | -48.3% | +45.0% | +168.9% | +82.5% | +180.9% | -30.9% | -63.3% | |
| Quick Ratio | 12.98 | 12.98 | 3.84 | 3.54 | 4.90 | 5.59 | 6.35 | 7.07 | 11.92 | 10.56 | 12.28 | 4.67 | 4.43 |
| — | +132.3% | -39.5% | -49.9% | -58.9% | -47.1% | -48.3% | +51.5% | +168.9% | +82.3% | +180.9% | -32.9% | -63.5% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 22 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying ATHE stock.
Alterity Therapeutics Limited's current P/E is -5.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Alterity Therapeutics Limited's current operating margin is -268.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Alterity Therapeutics Limited's business trajectory between earnings reports.